Johnson & Johnson's (JNJ - Free Report) Janssen Research & Development, LLC announced that the FDA has granted Breakthrough Therapy Designation (BTD) to esketamine, an experimental antidepressant treatment. The designation was granted for major depressive disorder with imminent risk for suicide.
This is the second indication for which esketamine got BTD in the U.S. Esketamine had previously got this designation in Nov 2013 for treatment-resistant depression. Esketamine is currently in phase III development for treatment-resistant depression.
According to information provided by the Centers for Disease Control and Prevention, there are more than 41,000 suicides each year in the U.S. with many resulting from untreated or poorly treated major depression.
We note that J&J recently got BTD for two other drugs as well. In Jul 2016, the company’s cancer treatment, Darzalex (daratumumab) got the designation for use in combination with standard of care regimens for multiple myeloma patients.
Earlier in Jun 2016, the company and its partner AbbVie Inc. (ABBV - Free Report) got a fourth BTD for Imbruvica. The FDA granted BTD to Imbruvica for the treatment of chronic graft-versus-host-disease (cGVHD) after one or more lines of systemic therapy have failed. Imbruvica was also granted Orphan Drug Designation for the indication.
BTD helps fasten the development and review of drugs which are being evaluated for the treatment of serious or life-threatening conditions and where preliminary clinical evidence indicates that the drug may be substantially better than existing treatments on clinically significant endpoint(s).
J&J is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Actelion Ltd. and Geron Corporation (GERN - Free Report) – both are Zacks Rank #1 (Strong Buy) stocks.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Johnson & Johnson's (JNJ - Free Report) Janssen Research & Development, LLC announced that the FDA has granted Breakthrough Therapy Designation (BTD) to esketamine, an experimental antidepressant treatment. The designation was granted for major depressive disorder with imminent risk for suicide.
This is the second indication for which esketamine got BTD in the U.S. Esketamine had previously got this designation in Nov 2013 for treatment-resistant depression. Esketamine is currently in phase III development for treatment-resistant depression.
According to information provided by the Centers for Disease Control and Prevention, there are more than 41,000 suicides each year in the U.S. with many resulting from untreated or poorly treated major depression.
We note that J&J recently got BTD for two other drugs as well. In Jul 2016, the company’s cancer treatment, Darzalex (daratumumab) got the designation for use in combination with standard of care regimens for multiple myeloma patients.
Earlier in Jun 2016, the company and its partner AbbVie Inc. (ABBV - Free Report) got a fourth BTD for Imbruvica. The FDA granted BTD to Imbruvica for the treatment of chronic graft-versus-host-disease (cGVHD) after one or more lines of systemic therapy have failed. Imbruvica was also granted Orphan Drug Designation for the indication.
BTD helps fasten the development and review of drugs which are being evaluated for the treatment of serious or life-threatening conditions and where preliminary clinical evidence indicates that the drug may be substantially better than existing treatments on clinically significant endpoint(s).
J&J is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Actelion Ltd. and Geron Corporation (GERN - Free Report) – both are Zacks Rank #1 (Strong Buy) stocks.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on JNJ - FREE
Get the latest research report on GERN - FREE
Get the latest research report on ABBV - FREE